Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02187861
Title A Study Evaluating the Safety and Efficacy of GDC-0199 (ABT-199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or GDC-0199 Plus Rituximab in Patients With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors Hoffmann-La Roche
Indications

follicular lymphoma

Therapies

Bendamustine + Rituximab

Bendamustine + Rituximab + Venetoclax

Rituximab + Venetoclax

Age Groups: adult
Covered Countries USA | ITA | FRA | DEU | CAN | BEL


No variant requirements are available.